- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS - Phase 1 LUMINA trial of AMX0114 underway; early ...

Please provide your email address to receive an email when new articles are posted on . AMX0114 was developed to target calpain-2, a driver of axonal neurodegeneration. A pending clinical trial will ...

AMX0114 is an investigational antisense oligonucleotide targeting calpain-2, a calcium-activated protease believed to play a role in ALS disease progression. The Food and Drug Administration (FDA) has ...

A recent large study conducted in Sweden has found that long-term exposure to elevated levels of air pollution may increase the risk for the development of motor neuron disease (MND), as well as ...

~ Designation enables an enhanced development path for VTx-002 and underscores its disease-modifying potential in ALS, a universally fatal disease with no cure ~ Milestone follows recent IND clearance ...

Darin Nakakihara doesn’t remember much from the day changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, and ...